치매 시장 - 시장 인사이트, 역학, 시장 예측(2034년)

Key Highlights:

• Dementia refers to a group of symptoms affecting memory, thinking, and social abilities severely enough to interfere with daily life. It is not a single disease, but rather an umbrella term that encompasses a range of specific medical conditions.
• Many medical conditions can cause or be associated with dementia beyond the primary classic types like Alzheimer's, vascular dementia, Lewy body dementia, and frontotemporal dementia. These conditions lead to dementia either directly through brain changes or indirectly via injuries, toxins, or systemic disease.
• According to WHO, Alzheimer disease is the most common form of dementia and may contribute to 60-70% of cases.
• The primary approved treatments for dementia, especially for Alzheimer's disease which is the most common type, are divided into two main categories: symptom-relief medications and disease-modifying therapies. Symptomatic treatments have been available for many years, whereas disease-modifying therapies have only recently entered clinical use.
• In June 2021, ADUHELM (aducanumab) received accelerated approval in the US, becoming the first Alzheimer's disease treatment to target a core pathological hallmark-amyloid beta plaque accumulation in the brain. However, its use remained limited due to safety concerns, insufficient evidence of clinical benefit, and a lack of widespread insurance coverage. As a result, in January 2024, Biogen discontinued the development and commercialization of ADUHELM.
• As of 2025, LEQEMBI and KISUNLA are the latest approved anti-amyloid therapies for early-stage Alzheimer's associated dementia. Symptomatic treatments like Donepezil, Rivastigmine, Galantamine, and Memantine remain widely used, primarily for Alzheimer's but also beneficial in Lewy body, Parkinson's disease dementia, and mixed types. However, other dementias types such as frontotemporal and vascular still lack approved targeted disease-modifying therapies.
• In January 2025, Eisai and Biogen announced that the US FDA approved the Supplemental Biologics License Application (sBLA) for LEQEMBI (lecanemab-irmb), authorizing a new IV maintenance dosing regimen of once every four weeks.
• The dementia treatment pipeline includes promising investigational therapies such as Masupirdine, Latozinemab (AL001), AL101 (GSK4527226), among others, reflecting ongoing efforts to address various forms and symptoms of the disease.
• In April 2025, Alector, announced the completion of enrollment in PROGRESS-AD, a 76-week Phase II clinical trial. The study is evaluating the safety and efficacy of AL101 (GSK4527226) in slowing disease progression in individuals with early Alzheimer's disease.
• Latozinemab, is the leading therapy in development for frontotemporal dementia due to progranulin gene mutation, has gained significant regulatory momentum with Orphan Drug, Breakthrough Therapy, and Fast Track designations.

DelveInsight's comprehensive report titled "Dementia - Market Insights, Epidemiology, and Market Forecast - 2034" offers a detailed analysis of dementia. The report presents historical and projected epidemiological data covering total Prevalent cases, total diagnosed prevalent cases, type-specific cases, gender-specific cases, and treated cases of Dementia. In addition to epidemiology, the market report encompasses various aspects related to the patient population. These aspects include the diagnosis process, prescription patterns, physician perspectives, market accessibility, treatment options, and prospective developments in the market across seven major markets: the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, spanning from 2020 to 2034.

The report analyzes the existing treatment practices and unmet medical requirements in dementia. It evaluates the market potential and identifies potential business prospects for enhancing therapies or interventions. This valuable information enables stakeholders to make well-informed decisions regarding product development and strategic planning for the market.

Dementia Overview

Dementia is a general term for a decline in cognitive function severe enough to interfere with daily life, most commonly caused by Alzheimer's disease. It encompasses a group of progressive neurological disorders that affect memory, thinking, behavior, and the ability to perform everyday activities. Other major types include Lewy body dementia, vascular dementia, frontotemporal dementia, and mixed forms. Dementia primarily affects older adults, but it is not a normal part of aging. With a growing aging population globally, dementia represents a significant public health challenge with increasing socioeconomic impact.

Dementia Diagnosis and Treatment Algorithm

Diagnosing dementia involves a comprehensive clinical assessment that includes medical history, cognitive testing, neurological examinations, laboratory work, and neuroimaging. Tools such as the Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) help evaluate cognitive deficits. MRI or CT scans may be used to rule out other causes and assess brain changes. In Alzheimer's disease, biomarkers like amyloid beta and tau proteins detected via PET imaging or cerebrospinal fluid, can aid in confirming diagnosis, especially in early or atypical cases. Early diagnosis is critical for management and planning.

While there is currently no cure for dementia, treatment aims to manage symptoms and, in some cases, slow disease progression. Symptomatic drugs such as Donepezil, Rivastigmine, Galantamine, and Memantine are commonly used to enhance cognition and daily function, primarily in Alzheimer's and some other dementias. Disease-modifying therapies like LEQEMBI, KISUNLA, and others are approved for early-stage Alzheimer's with confirmed amyloid pathology, offering new hope by targeting underlying disease mechanisms. Supportive care, behavioral therapies, caregiver education, and lifestyle interventions also play vital roles in comprehensive dementia management.

Dementia Epidemiology

The epidemiology section of the dementia market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.

This section also presents the data with relevant tables and graphs, offering a clear and concise view of the prevalence of dementia. Additionally, the report discloses the assumptions made during the analysis, ensuring data interpretation and presentation transparency. This epidemiological data is valuable for understanding the disease burden and its impact on the patient population across various regions.

• According to WHO, approximately 55 million people worldwide are currently living with dementia. . Alzheimer's disease and other forms of dementia ranked as the 7th leading cause of death.
• As per the secondary analysis, globally, the number of people affected by dementia was estimated to have increased, largely due to population ageing
• Women are disproportionately affected by dementia, both directly and indirectly. Women experience higher disability-adjusted life years and mortality due to dementia.
• The epidemiology of dementia is expected to change during the forecast period (2025-2034).

Dementia Market Outlook

The dementia therapeutics market is expected to witness steady growth over the forecast period (2025-2034), driven by rising global prevalence, growing awareness, improved diagnostic capabilities, and advancements in targeted therapies.

• While current treatment options largely focus on symptom management, the emergence of disease-modifying therapies particularly for early-stage Alzheimer's, signals a shift toward more proactive intervention.
• Dementia remains a significant area of unmet medical need, with most non-Alzheimer's subtypes e.g., frontotemporal, vascular, still lacking approved targeted treatments.
• A robust pipeline featuring novel agents such as masupirdine, latozinemab (AL001), AL101 (GSK4527226), and other biologics and small molecules is poised to transform the treatment landscape over the next decade.

Dementia Drug Chapters

Marketed Dementia Drugs

LEQEMBI (lecanemab-irmb): Biogen/Eisai

LEQEMBI (lecanemab), developed by Eisai and Biogen, is a humanized monoclonal antibody approved by the FDA in January 2023 under accelerated approval and granted traditional approval on July 2023. It is the first disease-modifying therapy shown to slow cognitive and functional decline in adults with early-stage Alzheimer's disease, including mild cognitive impairment and mild dementia, in patients with confirmed amyloid beta pathology.

LEQEMBI works by targeting and clearing both soluble and insoluble amyloid beta plaques in the brain, a core feature of Alzheimer's pathology. Administered as a 100 mg/mL intravenous infusion every two weeks, its clinical benefit was demonstrated in the Phase III Clarity AD trial. However, treatment requires MRI monitoring due to risks of amyloid-related imaging abnormalities (ARIA), including brain swelling and microbleeds.

KISUNLA (donanemab-azbt): Eli Lilly and Company

KISUNLA (donanemab-azbt) is an amyloid-targeting treatment for people with mild cognitive impairment (MCI) as well as people with mild dementia stage of early symptomatic Alzheimer's disease, with confirmed amyloid pathology. Kisunla can cause serious side effects, including amyloid-related imaging abnormalities, or ARIA, and infusion-related reactions. Kisunla is a prescription medicine administered intravenously every four weeks, 700 mg for the first three doses and 1400 mg thereafter.

In July 2024, the FDA approved KISUNLA, Eli Lilly's treatment for adults with early symptomatic Alzheimer's disease, including mild cognitive impairment and mild dementia with confirmed amyloid pathology.

Emerging Dementia Drugs

Latozinemab (AL001): Alector

AL001 is designed to modulate progranulin (PGRN), a crucial regulator of immune activity in the brain that has been genetically linked to several neurodegenerative disorders. The therapy is currently being developed for frontotemporal dementia (FTD) associated with progranulin mutations (FTD-GRN). The global Phase III clinical trial, INFRONT-3, is actively enrolling both symptomatic individuals and those at risk for FTD-GRN, aiming to evaluate the therapeutic potential of AL001 in altering disease progression.

In September 2024, Alector, presented a poster detailing participant baseline characteristics from the pivotal INFRONT-3 Phase III clinical trial. The presentation took place at a scientific conference held in Amsterdam from September 19-22, 2024.

Masupirdine (SUVN-502): Suven Life Sciences

Masupirdine is a highly selective 5-HT6 receptor antagonist, nonclinical studies have shown that it is orally bioavailable, safe, and effective. In Phase I trials, Masupirdine demonstrated a favorable safety profile and was well tolerated in healthy volunteers. It was later assessed in a Phase II study (NCT02580305) in Alzheimer's disease patients, where subgroup analyses indicated a significant reduction in neuropsychiatric symptoms, particularly agitation and aggression.

A global Phase III pivotal trial (NCT05397639; EudraCT: 2021-003405-22) is currently underway to evaluate its efficacy and safety in treating agitation associated with Alzheimer's disease. The trial aims to enroll 375 patients, with completion expected by the end of 2026.

Dementia Market Segmentation

DelveInsight's 'Dementia - Market Insights, Epidemiology, and Market Forecast - 2034' report provides a detailed outlook of the current and future dementia market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies.

Dementia Market Size by Countries

The dementia market size is assessed separately for various countries, including the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. In 2024, the United States held a significant share of the overall 7MM (Seven Major Markets) dementia market. This dominance is projected to persist, especially with the potential introduction of new products.

Dementia Drugs Uptake

This section focuses on the sales uptake of potential dementia drugs that have recently been launched or are anticipated to be launched in the dementia market between 2020 and 2034. It estimates the market penetration of dementia drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the dementia market.

The emerging dementia therapies are analyzed based on various attributes such as safety and efficacy in randomized clinical trials, order of entry and other market dynamics, and the unmet need they fulfill in the dementia market.

Dementia Market Access and Reimbursement

DelveInsight's 'Dementia - Market Insights, Epidemiology, and Market Forecast - 2034' report provides a descriptive overview of the market access and reimbursement scenario of dementia.

This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments.

KOL Views

To keep up with current dementia market trends and fill gaps in secondary findings, we interview KOLs and SMEs' working in the dementia domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or dementia market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the dementia unmet needs.

DelveInsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 25+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as University of California, Johns Hopkins University, University of Exeter, German Center for Neurodegenerative Diseases (DZNE), ellvitge-Idibell University Hospital, University of Leeds, and University of Tokyo, among others.

Competitive Intelligence Analysis

We conduct a Competitive and Market Intelligence analysis of the dementia Market, utilizing various Competitive Intelligence tools such as SWOT analysis and Market entry strategies. The inclusion of these analyses is contingent upon data availability, ensuring a comprehensive and well-informed assessment of the market landscape and competitive dynamics.

Dementia Pipeline Development Activities

The report offers an analysis of therapeutic candidates in Phase II and III stages and examines companies involved in developing targeted therapeutics for dementia. It provides valuable insights into the advancements and progress of potential treatments in clinical development for this condition.

Pipeline Development Activities

The report covers information on collaborations, acquisition and merger, licensing, patent details, and other information for emerging dementia therapies.

Dementia Report Insights

• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of Upcoming Therapies

Dementia Report Key Strengths

• 10 Years Forecast
• The 7MM Coverage
• Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Dementia Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness

Key Questions:

• How common is dementia?
• What are the key findings of dementia epidemiology across the 7MM, and which country will have the highest number of patients during the study period (2020-2034)?
• What are the currently available treatments for dementia?
• What are the disease risk, burden, and unmet needs of dementia?
• At what CAGR is the dementia market and its epidemiology is expected to grow in the 7MM during the forecast period (2025-2034)?
• How would the unmet needs impact the dementia market dynamics and subsequently influence the analysis of the related trends?
• What would be the forecasted patient pool of dementia in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
• Among EU4 and the UK, which country will have the highest number of patients during the forecast period (2025-2034)?
• How many companies are currently developing therapies for the treatment of dementia?

Reasons to buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the dementia market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of current treatment in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Frequently Asked Questions

1. What are the treatment goals for dementia?

The primary goals of dementia treatment are to slow disease progression, manage cognitive and behavioral symptoms, and enhance quality of life. This includes preserving daily functioning, addressing issues like agitation or depression, ensuring patient safety, and providing support to caregivers. While disease-modifying therapies are emerging for early-stage Alzheimer's, overall care remains focused on symptom relief and personalized support across all stages and dementia subtypes.

2. What are the challenges in managing dementia?

Managing dementia presents several challenges, including the progressive and irreversible nature of the disease, variability across subtypes, and limited availability of disease-modifying treatments. Early diagnosis is often missed due to subtle initial symptoms, and managing behavioral and psychological symptoms such as agitation, aggression, and depression can be complex. Additionally, there are challenges in ensuring consistent, long-term care, addressing caregiver burden, and coordinating multidisciplinary support. Socioeconomic factors, stigma, and disparities in access to care further complicate effective dementia management.

3. What are the key factors driving the growth of the dementia market?

Key growth factors include the approval of disease-modifying therapies like LEQEMBI and KISUNLA, advancements in diagnostic tools and biomarkers, increasing government funding, and the integration of digital health technologies. Additionally, ongoing innovation in R&D and AI-driven drug discovery is accelerating the development of novel therapies, positioning dementia as a major focus area in the neurodegenerative disease landscape.

4. How will the Dementia Market and Epidemiology Forecast Report benefit the clients?

The report will provide comprehensive insights into the current dementia market landscape, emerging therapies, competitive dynamics, regulatory requirements, and market access considerations, enabling informed decision-making, strategic planning, and optimization of business strategies to capitalize on market opportunities and drive growth.

Table of Contents

1. Key Insights

2. Report Introduction

3. Market Overview at a Glance

3.1.. Market Share (%) Distribution by Therapies in 2024

3.2.. Market Share (%) Distribution by Therapies in 2034

4. Epidemiology and Market Methodology

5. Executive Summary

6. Key Events

7. Disease Background and Overview

7.1.. Introduction

• 7.2. Types

7.3.. Causes

7.4.. Pathophysiology

7.5.. Symptoms

7.6.. Risk Factor

7.7.. Diagnosis

7.7.1.. Diagnostic Algorithm

7.7.2.. Diagnostic Guidelines

7.8.. Treatment and Management

7.8.1.. Treatment Algorithm

7.8.2.. Treatment Guidelines

8. Epidemiology and Patient Population

• 8.1. Key Findings
• 8.2. Assumptions and Rationale: The 7MM
• 8.3. Total Prevalent Cases of Dementia in the 7MM
• 8.4. The US
  • 8.4.1. Total Prevalent Cases of Dementia
  • 8.4.2. Total Diagnosed Prevalent Cases of Dementia
  • 8.4.3. Type-specific Cases of Dementia
  • 8.4.4. Gender-specific Cases of Dementia
  • 8.4.5. Treated Cases of dementia
• 8.5. EU4 and the UK
  • 8.5.1. Total Prevalent Cases of Dementia
  • 8.5.2. Total Diagnosed Prevalent Cases of Dementia
  • 8.5.3. Type-specific Cases of Dementia
  • 8.5.4. Gender-specific Cases of Dementia
  • 8.5.5. Treated Cases of dementia
• 8.6. Japan
  • 8.6.1. Total Prevalent Cases of Dementia
  • 8.6.2. Total Diagnosed Prevalent Cases of Dementia
  • 8.6.3. Type-specific Cases of Dementia
  • 8.6.4. Gender-specific Cases of Dementia
  • 8.6.5. Treated Cases of dementia

9. Patient Journey

10. Marketed Therapies

• 10.1. Key Cross
• 10.2. LEQEMBI (lecanemab-irmb): Biogen/Eisai
  • 10.2.1. Drug Description
  • 10.2.2. Other Development Activities
  • 10.2.3. Clinical Trials Information
  • 10.2.4. Safety and Efficacy
  • 10.2.5. Analysts' Views

11. Emerging Therapies

• 11.1. Key Cross
• 11.2. Latozinemab (AL001): Alector
  • 11.2.1. Drug Description
  • 11.2.2. Other Development Activities
  • 11.2.3. Clinical Trials Information
  • 11.2.4. Safety and Efficacy
  • 11.2.5. Analysts' Views

12. Dementia: Seven Major Market Analysis

• 12.1. Key Findings
• 12.2. Key Market Forecast Assumptions
  • 12.2.1. Cost Assumptions and Rebates
  • 12.2.2. Pricing Trends
  • 12.2.3. Analogue Assessment
  • 12.2.4. Launch Year and Therapy Uptake
• 12.3. Market Outlook
• 12.4. Conjoint Analysis
• 12.5. Total Market Size of Dementia in the 7MM
• 12.6. Market Size of Dementia by Therapies in the 7MM
• 12.7. The US Market Size
  • 12.7.1. Total Market Size of Dementia
  • 12.7.2. Market Size of Dementia by Therapies
• 12.8. EU4 and the UK Market Size
  • 12.8.1. Total Market Size of Dementia
  • 12.8.2. Market Size of Dementia by Therapies

12.9.. Japan Market Size

• 12.9.1. Total Market Size of Dementia
• 12.9.2. Market Size of Dementia by Therapies

13. Key Opinion Leaders' Views

14. Unmet Needs

15. SWOT Analysis

16. Dementia Market Access and Reimbursement

• 16.1. United States
  • 16.1.1. Centre for Medicare and Medicaid Services (CMS)
• 16.2. EU4 and the UK
  • 16.2.1. Germany
  • 16.2.2. France
  • 16.2.3. Italy
  • 16.2.4. Spain
  • 16.2.5. United Kingdom
• 16.3. Japan
  • 16.3.1. MHLW

17. Appendix

• 17.1. Bibliography
• 17.2. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight